D. Clark

发表

Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.

T. Kotsimbos, A. Tierney, B. Button, 2017, Clinical science.

Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration

J. Li, R. Nation, C. Porter, 2014, Antimicrobial Agents and Chemotherapy.

Inhalational Administration Patients: Targeting Advantage of Methanesulfonate in Cystic Fibrosis of Inhaled and Intravenous Colistin Pulmonary and Systemic Pharmacokinetics

Jian Li, C. Porter, John W. Wilson, 2014 .

WS14.1 Ivacaftor improves exercise capacity in patients with G551D CF gene mutations

T. Kotsimbos, A. Tierney, B. Button, 2015 .

ePS03.4 Patient reported adherence to ivacaftor

T. Kotsimbos, A. Tierney, B. Button, 2015 .

ePS05.3 Ivacaftor and its effects on body composition in adults with G551D related cystic fibrosis

T. Kotsimbos, A. Tierney, B. Button, 2015 .

WS09.5 Effect of ivacaftor on wellness, quality of life and cognitive function in adults with cystic fibrosis and G551D mutation

T. Kotsimbos, A. Tierney, B. Button, 2015 .

73 The effect of ivacaftor CFTR gene-potentiating therapy on cytokine levels in CF patients with the G551D mutation

T. Kotsimbos, N. Mifsud, John W. Wilson, 2017 .